Jazz investors and execs cash in on Azur merger and increased sales
This article was originally published in Scrip
Executive Summary
A number of Jazz Pharmaceuticals investors are taking advantage of the Dublin company's US stock price being at six times its August 2010 value to cash in some of their ordinary shares during an offering that will close on 9 March.